Efficacy of Communication Bridge-2 for primary progressive aphasia: A randomized controlled trial of communication intervention

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-03-27 DOI:10.1002/alz.70088

Emily Rogalski, Matthew Bona, Marissa Esparza, Ollie Fegter, Rhiana Schafer, Aimee Mooney, Melanie Fried-Oken, Alfred Rademaker, Angela Roberts

{"title":"Efficacy of Communication Bridge-2 for primary progressive aphasia: A randomized controlled trial of communication intervention","authors":"Emily Rogalski, Matthew Bona, Marissa Esparza, Ollie Fegter, Rhiana Schafer, Aimee Mooney, Melanie Fried-Oken, Alfred Rademaker, Angela Roberts","doi":"10.1002/alz.70088","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Primary progressive aphasia (PPA), a language-based neurodegenerative dementia, negatively impacts communication and quality of life. Previous non-pharmacologic interventions show promise but lack efficacy trials. Here, outcomes are provided from Communication Bridge-2 (CB2), a speech-language randomized controlled trial (RCT) for PPA.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>CB2 is the first Phase 2, Stage II, parallel-group RCT delivered via video chat with global enrollment. Ninety-five dyads were randomized into one of two speech-language intervention arms. Primary outcomes included communication confidence and participation measures. Marginal linear models assessed efficacy across ≈12 months.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Ninety-five dyads were randomized from four countries. Experimental arm superiority in communication-participation measurement of goal attainment was demonstrated (66.7% vs 49.1%, respectively, <i>p </i>= 0.006), and corroborated by post-study interviews.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Outcomes demonstrate the feasibility and initial efficacy of a person-centered telemedicine intervention for maximizing communication participation for mild-to-moderate PPA, providing a pathway for developing and implementing clinically meaningful interventions for Alzheimer's disease and related dementias.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Primary progressive aphasia (PPA) negatively impacts communication participation.</li>\n \n <li>Communication Bridge-2 (CB2) is a telemedicine-delivered randomized controlled trial (RCT).</li>\n \n <li>Global recruitment of 95 PPA participant dyads into an RCT with low dropout.</li>\n \n <li>First international superiority trial for PPA using video chat shows efficacy.</li>\n \n <li>The study provides a model for rigorous non-pharmacologic trials for Alzheimer's disease/Alzheimer's disease and related dementias (AD/ADRD).</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 3","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70088","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70088","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Primary progressive aphasia (PPA), a language-based neurodegenerative dementia, negatively impacts communication and quality of life. Previous non-pharmacologic interventions show promise but lack efficacy trials. Here, outcomes are provided from Communication Bridge-2 (CB2), a speech-language randomized controlled trial (RCT) for PPA.

METHODS

CB2 is the first Phase 2, Stage II, parallel-group RCT delivered via video chat with global enrollment. Ninety-five dyads were randomized into one of two speech-language intervention arms. Primary outcomes included communication confidence and participation measures. Marginal linear models assessed efficacy across ≈12 months.

RESULTS

Ninety-five dyads were randomized from four countries. Experimental arm superiority in communication-participation measurement of goal attainment was demonstrated (66.7% vs 49.1%, respectively, p = 0.006), and corroborated by post-study interviews.

DISCUSSION

Outcomes demonstrate the feasibility and initial efficacy of a person-centered telemedicine intervention for maximizing communication participation for mild-to-moderate PPA, providing a pathway for developing and implementing clinically meaningful interventions for Alzheimer's disease and related dementias.

Highlights

Primary progressive aphasia (PPA) negatively impacts communication participation.
Communication Bridge-2 (CB2) is a telemedicine-delivered randomized controlled trial (RCT).
Global recruitment of 95 PPA participant dyads into an RCT with low dropout.
First international superiority trial for PPA using video chat shows efficacy.
The study provides a model for rigorous non-pharmacologic trials for Alzheimer's disease/Alzheimer's disease and related dementias (AD/ADRD).

Abstract Image

查看原文本刊更多论文

引言原发性进行性失语症（PPA）是一种以语言为基础的神经退行性痴呆症，对交流和生活质量产生负面影响。以往的非药物干预措施显示了其前景，但缺乏疗效试验。本文提供了 "沟通之桥-2"（CB2）的研究结果，这是一项针对 PPA 的言语-语言随机对照试验（RCT）。方法 CB2 是首个通过视频聊天进行的第二阶段平行组 RCT，全球范围内均可报名参加。95 对夫妇被随机分配到两个语言干预组中的一个。主要结果包括沟通信心和参与度。边际线性模型评估了≈12 个月的疗效。结果来自四个国家的 95 对夫妇被随机分配。实验臂在目标实现的沟通-参与测量方面表现出优势（分别为 66.7% 对 49.1%，p = 0.006），并得到了研究后访谈的证实。讨论结果表明，以人为本的远程医疗干预措施对轻度至中度 PPA 患者最大限度地参与交流具有可行性和初步疗效，为开发和实施对阿尔茨海默病和相关痴呆症有临床意义的干预措施提供了途径。亮点原发性进行性失语症（PPA）对交流参与产生负面影响。沟通之桥-2（CB2）是一项远程医疗随机对照试验（RCT）。在全球范围内招募了 95 对 PPA 参与者组合参加 RCT，辍学率较低。国际上首次使用视频聊天进行的 PPA 优越性试验显示了疗效。该研究为阿尔茨海默病/阿尔茨海默病及相关痴呆症（AD/ADRD）的严格非药物试验提供了一个范例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.